Results 241 to 250 of about 741,833 (341)

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi   +100 more
wiley   +1 more source

Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population‐Based Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Fentanyl, hydromorphone, and oxycodone are metabolized by cytochrome P450 3A4 (CYP3A4). Co‐administration with CYP3A4‐inhibiting macrolides (clarithromycin or erythromycin) may increase opioid concentrations and overdose risk, but the clinical impact of these interactions is unknown.
Tony Antoniou   +7 more
wiley   +1 more source

Assessing the adequacy of funding for robotic-surgery hospital stays: a focused cost analysis based on 1,722 procedures in a French university hospital. [PDF]

open access: yesJ Robot Surg
Lacassagne A   +13 more
europepmc   +1 more source

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu   +2 more
wiley   +1 more source

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. <i>Cancers</i> 2026, <i>18</i>, 124. [PDF]

open access: yesCancers (Basel)
Pourroy B   +22 more
europepmc   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy